Combination of Nivolumab and Ipilimumab Yields Better Outcomes Compared to Ipilimumab Alone in Patients with Advanced Melanoma and Primary Resistance to anti-PD1 or anti-PD-L1 Therapy
Findings from the S1616 study
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1548 results
Limited Efficacy of Nivolumab plus Ipilimumab in Adenoid Cystic Carcinomas, but Promising for Salivary Duct Carcinomas
Findings from a phase II study
FDA Approves Melphalan As a Liver-Directed Treatment for Uveal Melanoma
Evidence for efficacy is based on the results from the FOCUS study
EMA Recommends Granting a Marketing Authorisation for Crisantaspase
It is intended for the treatment of acute lymphoblastic leukaemia and lymphoblastic lymphoma in patients who developed hypersensitivity or silent inactivation to E. coli-derived asparaginase
OncoNPC Classifier Identifies CUP Subgroups Sharing Characteristics with Predicted Primaries and Significant Differences in Outcomes and Elevated Germline Risk
Through a machine-learning model, many carcinomas of unknown primary can be classified into meaningful subgroups with the potential to aid clinical decision making
Encouraging Single-Agent Antitumour Activity of Divarasib Across KRAS G12C-positive Tumours
Findings from the GO42144 study
Binimetinib Contributes to the Efficacy and Safety Outcomes Observed with Encorafenib Plus Binimetinib Combination Therapy in Patients with BRAFV600-mutated Melanoma
Findings from the COLUMBUS part 2 study
FDA Approves Pralsetinib for Non-Small Cell Lung Cancer with RET Gene Fusions
Conversion to regular approval is based on data from additionally included patients and additional follow-up in the ARROW study
EMA Recommends Granting a Marketing Authorisation for Decitabine / Cedazuridine
It is indicated for the treatment of adult patients with newly diagnosed AML who are ineligible for standard induction chemotherapy
Activity and Safety of Atezolizumab Combined with Carboplatin and Pemetrexed in Patients with Untreated Brain Metastases from Non-squamous NSCLC
Findings from the Atezo-Brain study
A Combination of Durvalumab-Tremelimumab with mFOLFOX6 Is Tolerable with Promising Activity in Patients with Microsatellite Stable Metastatic Colorectal Cancer
Findings from the MEDITREME study
Efficacy and Safety of Elranatamab, BCMA-CD3 Bispecific Antibody, in Patients with Relapsed or Refractory Multiple Myeloma
Findings from the registrational phase II MagnetisMM-3 study